TLR7 and neoplasm: The integration of a TLR7/8 agonist into our KRASG12D LNPs aligns with our overarching strategy of enhancing antigen presentation while simultaneously overcoming immune suppression in PDAC.[7, 45] Transcriptomic analyses in our study revealed a significant upregulation of MHC I‐ and MHC II‐associated components following combination therapy, indicating improved cross‐presentation of tumor antigens to CD8+ T cells, as well as enhanced CD4+ T cell activation.